Document is current
Any future updates will be listed below
-
Authors
Yi, Tae Won https://orcid.org/0000-0003-3350-1170
Sridhar, Vikas S.
Scott, Jennifer https://orcid.org/0000-0001-8837-5250
Nardone, Massimo
Cherney, David https://orcid.org/0000-0003-4164-0429
- License Information
-
More Information
Article History
Accepted: 28 November 2025
First Online: 12 January 2026
Competing interests
: T.W.Y. has received conference and travel support from Lexicon Pharmaceuticals and Boehringer Ingelheim. V.S.S. has received conference and travel support from Merck Canada and Lexicon Pharmaceuticals and received advisory board fees from Novo Nordisk Canada. J.S. has received speaker fees from CSL Vifor. M.N. declares no competing interests. D.C reports serving or having served as a consultant for Boehringer Ingelheim-Lilly, Merck, AstraZeneca, Sanofi, Mitsubishi-Tanabe, AbbVie, Janssen, Bayer, Prometric, BMS, Maze, Gilead, CSL-Behring, Otsuka, Novartis, Youngene, Lexicon, Inversago, GSK and Novo-Nordisk. He has received operational funding from Boehringer Ingelheim-Lilly, Merck, Janssen, Sanofi, AstraZeneca, CSL-Behring and Novo-Nordisk.
